Congrats to the PR24 CCTG Phase III Team Award

The Team Awards for Phase III CCTG trials is presented to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance is determined by the Executive IND Committee and Clinical Trials Committee.

This year the CCTG Phase III Team Award goes to the PR.24 trial team at Trillium Health Partners – Credit Valley Hospital.  This team says, "This award is a meaningful acknowledgment of the dedication, collaboration, and commitment of our entire non-MD team. We take great pride in contributing to the success of the PR.24 trial through strong accrual, efficient activation timelines, and adherence to high compliance and performance standards. We would also like to acknowledge Dr. Yuen, our Local PI, for his unwavering leadership, partnership, and support, without which this achievement would not have been possible. We are grateful for the opportunity to be part of such impactful clinical research and to collaborate with the broader CCTG network. This recognition further motivates us to continue our important work in advancing cancer research and improving patient outcomes."

The PR24 ASCENDE-SBRT, trial aims to see around 710 participants randomized to receive five sessions of SABR or 23 whole pelvis radiation sessions and a brachytherapy boost. SABR involves higher dose per day treatments, delivered with pinpoint precision to target tumours. Brachytherapy is a form of targeted radiation that sees a tiny radioactive seed temporarily placed inside the prostate. Five treatments of SABR is now the standard of care for favourable risk prostate patients who are not eligible for active surveillance.